X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.393 0.0036 (0.92%) Market Cap: 67.03 Mil Enterprise Value: 10.25 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 30/100

X4 Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript

Aug 11, 2022 / 07:30PM GMT
Release Date Price: $1.43 (+11.72%)
Ben Shim
Canaccord Genuity - Analyst

(audio in progress) everybody and welcome to our afternoon session of the 42nd Annual Canaccord Genuity Growth Conference. I'm Ben Shim, a member of the biotech research team. It's my pleasure to introduce the management team of X4 Pharmaceuticals, Dr. Paula Ragan, CEO; and Adam Mostafa, CFO. Welcome and thanks for joining us.

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

Thank you so much for having us. And it's a great conference and place to be in person with everyone. And looking forward to the connection today.

Questions & Answers

Ben Shim
Canaccord Genuity - Analyst

For those who are new to the X4 story, can you maybe give us a brief background on what WHIM -- that's W-H-I-M -- syndrome is and how your drug, mavorixafor, is positioned to help this patient population?

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

Sure. So I'll start. So the company is really focused on making a difference

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot